Karyopharm Sales General And Administrative To Revenue from 2010 to 2024
| KPTI Stock | USD 0.64 0.01 1.54% |
Sales General And Administrative To Revenue | First Reported 2010-12-31 | Previous Quarter 0.9030904 | Current Value 0.86 | Quarterly Volatility 44.53688145 |
Check Karyopharm Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Karyopharm Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 503.5 K, Interest Expense of 25 M or Selling General Administrative of 67.5 M, as well as many indicators such as Price To Sales Ratio of 0.64, Dividend Yield of 0.0 or Days Sales Outstanding of 52.74. Karyopharm financial statements analysis is a perfect complement when working with Karyopharm Therapeutics Valuation or Volatility modules.
Karyopharm | Sales General And Administrative To Revenue |
Latest Karyopharm Therapeutics' Sales General And Administrative To Revenue Growth Pattern
Below is the plot of the Sales General And Administrative To Revenue of Karyopharm Therapeutics over the last few years. It is Karyopharm Therapeutics' Sales General And Administrative To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Karyopharm Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Sales General And Administrative To Revenue | 10 Years Trend |
|
Sales General And Administrative To Revenue |
| Timeline |
Karyopharm Sales General And Administrative To Revenue Regression Statistics
| Arithmetic Mean | 25.17 | |
| Geometric Mean | 5.52 | |
| Coefficient Of Variation | 176.95 | |
| Mean Deviation | 31.46 | |
| Median | 3.83 | |
| Standard Deviation | 44.54 | |
| Sample Variance | 1,984 | |
| Range | 155 | |
| R-Value | (0.27) | |
| Mean Square Error | 1,982 | |
| R-Squared | 0.07 | |
| Significance | 0.33 | |
| Slope | (2.67) | |
| Total Sum of Squares | 27,769 |
Karyopharm Sales General And Administrative To Revenue History
About Karyopharm Therapeutics Financial Statements
Investors use fundamental indicators, such as Karyopharm Therapeutics' Sales General And Administrative To Revenue, to determine how well the company is positioned to perform in the future. Although Karyopharm Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Sales General And Administrative To Revenue | 0.90 | 0.86 |
Currently Active Assets on Macroaxis
When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:Check out the analysis of Karyopharm Therapeutics Correlation against competitors. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 1.247 | Quarterly Revenue Growth 0.077 | Return On Assets (0.34) | Return On Equity (8.91) |
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.